Mednet Logo
SpecialtiesUrology
Urology

Urology

Expert guidance on urologic oncology, stone disease, BPH management, incontinence, and minimally invasive surgical approaches.

Recent Discussions

In a patient with biochemical recurrence after radical prostatectomy for pT2 disease and a high-risk Decipher genomic classifier, with a PSA of 0.7 ng/mL, is there a rationale for administering salvage radiation therapy to the prostate fossa?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology

Yes, salvage RT to the prostate fossa (+ ADT/ pelvic lymph nodes) would be considered the preferred option in this circumstance, in my opinion (see NCCN 2026.3). Despite the PSA being higher than is typical in 2026 and some risk factors for not responding to RT (e.g., margin-negative resection), it ...

Assuming approval, in which patients would you choose Belzutifan + Lenvatinib (LITESPARK-011) for advanced RCC, with progression after IO therapy?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · The University of Texas Health Science Center at San Antonio

LITESPARK-011 is an interesting study as it relates to current standard practice. Presently, lenvatinib/everolimus is a well-established and potent treatment option. Each clearly contributes towards the clinical benefit observed in most patients. For instance, in the study NCT01136733 (Motzer et al....

How do you approach management for recurrent stone formers who sleep over 8 hours per day and fail to reach 2.5 liters of daily urine output on 24 hour urine stone risk studies?

2 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

I suggest the patient plan a schedule by which they drink 2.5 L per day. To get started, I suggest they set their phone to alert them when it is time to drink the requisite amount of fluid, preferably water. After a while, this becomes an automatic habit. Stephen B. Erickson, MD

How would you approach adding ADT to salvage radiation therapy for a biochemically recurrent prostate cancer patient with very high Decipher but non-luminal B on PAM50?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Yes, especially if PSA is more than 0.5 ng/mL.

How long do you treat retroperitoneal fibrosis with immunosuppression?

4
1 Answers

Mednet Member
Mednet Member
Rheumatology · MUSC Health

I normally treat for 9 months to a year depending on response. I have found PET CT useful in determining if there is active ongoing inflammation.

Do you rely on urinalysis testing for microscopic hematuria as a means to assess for a ureteral stone for patients with recurrent nephrolithiasis who report mild potential stone-related pain?

4 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

No. I think hematuria is nonspecific as regards ureteral stones. I use imaging, preferably CT, although ultrasound, looking for hydroureter or even KUB, if positive, would suffice.

What are your recommendations in managing pudendal neuralgia/red scrotum syndrome?

1 Answers

Mednet Member
Mednet Member
Dermatology · Harvard Medical School/Brigham and Women’s Hospital

Red scrotum syndrome is very challenging to treat. The list of reported treatments is long, but I have not found one to be consistently effective. Treatment selection depends significantly on patient characteristics and preferences. In my opinion, every patient with red scrotum syndrome should under...

Do you consider estrogen patches in treatment of prostate cancer?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · VCU Massey Comprehensive Cancer Center

Oral estrogenic formulation (such as DES) was historically used for androgen suppression in prostate cancer patients. This was based on the principle that estrogen decreased serum testosterone levels by suppressing luteinizing hormone production through a negative feedback loop on the hypothalamus a...

Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

My default form of ADT remains a GnRH agonist or antagonist but estradiol transdermal patches are clearly effective and safe as an alternative option for men who either 1) have significant loss of bone density/osteoporosis, 2) have significant hot flashes with traditional ADT and wish to try an alte...

How do you approach management of a patient with intermediate risk prostate cancer treated upfront with HIFU and intermittent ADT who is later found to have rising PSA and biopsy-proven prostate-confined recurrence?

3
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Utah School of Medicine

These are frustrating situations, and ones I am now seeing frequently as focal therapies have gained traction in the United States. The approach, needless to say, is highly individualized. Often, these glands are quite abnormal in MRI appearance, and there is a concern for fibrosis. My approach is h...